Evidence map›Paper›PMID 28376165›Full record

ArticleJournal of the National Cancer Institute2017

Current State of PCR-Based Epstein-Barr Virus DNA Testing for Nasopharyngeal Cancer.

Kelly Y Kim, Quynh-Thu Le, Sue S Yom, Benjamin A Pinsky, Scott V Bratman, Raymond H W Ng, Haja S El Mubarak, K C Allen Chan, Miriam Sander, Barbara A Conley

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Cancer Institute, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

Kelly Y KimCancer Diagnosis Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Quynh-Thu LeDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Sue S YomDepartment of Radiation Oncology, University of California, San Francisco, CA, USA.
Benjamin A PinskyDepartments of Pathology and Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Scott V BratmanDepartment of Radiation Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Ontario, Canada.
Raymond H W NgDepartment of Otolaryngology, Head and Neck Surgery, University of Toronto, Toronto, Ontario, Canada.
Haja S El MubarakDivision of Microbiology Devices, Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, MD, USA.
K C Allen ChanDepartment of Chemical Pathology, State Key Laboratory in Oncology of South China, The Chinese University of Hong Kong, Hong Kong SAR, China.
Miriam SanderPage One Editorial Services, Boulder, CO, USA.
Barbara A ConleyCancer Diagnosis Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Chinese University of Hong Kong · CNPrincess Margaret Cancer Centre · CAStanford University · USUniversity of Toronto · CANational Cancer Institute · USUniversity of California, San Francisco · US

Funding

NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
NCI NIH HHS U10 CA180868
6 · The paper itself

Abstract

Clinical studies have shown plasma Epstein-Barr virus (EBV) DNA level to be an independent prognostic biomarker for nasopharyngeal carcinoma (NPC). However, the proportion of NPC patients whose tumors are associated with EBV vary with geographic location, and there are a variety of assays for plasma EBV. To develop the level of evidence needed to demonstrate the clinical utility of plasma EBV DNA detection for NPC patients and encourage widespread adoption of this biomarker test in clinical laboratories, validated harmonized assays are needed. In 2015, the National Cancer Institute (NCI) convened a Workshop on Harmonization of EBV Testing for Nasopharyngeal Cancer, where experts in head and neck oncology and laboratory medicine addressed the limitations of currently available polymerase chain reaction-based EBV DNA quantitation assays and discussed strategies for advancing the development of harmonized EBV DNA assays and their appropriate clinical use. This article presents the key recommendations to direct future efforts in assay harmonization and validation.

Indexed as

Biomarkers, TumorCongresses as TopicDNA, ViralHerpesvirus 4, HumanHumansNasopharyngeal NeoplasmsPolymerase Chain ReactionReproducibility of ResultsBiomarkers, TumorDNA, Viral

Identifiers

PMID28376165
PMCPMC6279258
OpenAlexW2607424519

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.